EGFR and non-small cell lung carcinoma: The randomized phase III TROPION-Lung01 study compared the efficacy and safety of datopotamab deruxtecan versus docetaxel in patients with pretreated advanced NSCLC, including patients with actionable genomic alterations such as EGFR mutations [53].